Objective -To examine the effect on total prescribing costs and prescribing costs for respiratory drugs for practices with at least one general practitioner with a special interest in asthma.
Introduction
The introduction of indicative prescribing budgets and the role of the new medical advisors to family health services authorities (FHSAs) in monitoring prescribing costs suggest that prescribing analyses and cost (PACT) data will become much more important. PACT data comprise a quarterly report on prescribing costs sent to all general practitioners in England and Wales from the Prescription Pricing Authority in Newcastle upon Tyne. Level 1 data give prescribing costs under several summary headings, but level 2 and 3 data, which are available on request, give more details concerning the individual drugs and preparations prescribed. Practices with high costs, either in total or in any of the subgroups based on the British National Formulary, may have to justify to the FHSA their apparent excess in drug expenditure.
At the same time general practitioners are being exhorted to make greater use of antiinflammatory drugs in treating asthma in adults' and children2 3 to suppress the inflammatory changes found in the bronchi of even mild asthmatic patients,4 to reduce the mortality and morbidity from asthma that has been called for in community care,5-7 and thus to improve the quality of care delivered to patients with asthma. However, these antiinflammatory medicines are expensive, and increases in their use will certainly raise prescribing costs for patients with respiratory conditions. What is not clear, however, is what influence such changes will have on overall prescribing costs. This paper reports a study of total prescribing costs and prescribing costs for respiratory drugs for general practitioners with a special interest in asthma (members of the General Practitioners in Asthma Group) and their practices and compares them with the average prescribing costs for their FHSA. The current prescribing costs for respiratory drugs for members of the group are predicted to reflect future trends in national prescribing costs if increased prescribing of antiinflammatory drugs does occur.
Subjects and methods
All 269 members of the General Practitioner in Asthma Group based in England and Wales received a single postal invitation to participate in the survey. One hundred and three members agreed to participate and were sent a questionnaire which asked for the following information: name of FHSA; list size (as stated on the PACT return); number of partners in the practice and their hours (26, 19, or 13); total prescribing costs; prescribing costs for respiratory drugs (including prophylactics) and for prophylactic respiratory drugs alone for the individual practitioner, the practice as a whole, and the average cost for the FHSA (not available for prophylactic drugs); and the quarter end date (the last available quarter of PACT data for 1989 was to be used). The quarter end date was needed because PACT data are supplied to general practitioners with differing dates, depending on geographical factors. The cost of prophylactic drugs was derived by recording the sums of sections 3-2 (inhaled corticosteroids) and 3-3 (sodium cromoglycate, nedocromil sodium, and ketotifen) of the PACT data. The questionnaire was accompanied by supporting notes explaining how to obtain the required level 1, 2, and 3 PACT reports. Nonresponders received a repeat questionnaire after about three weeks. It should be noted that prescribing costs for respiratory drugs also include those for drugs for allergic disorders (mainly antihistamines), respiratory stimulants, oxygen, mucolytics, aromatic inhalations, antitussives, and systemic nasal decongestants.
The total number of partners and their time commitments were used to compute a notional share of the list as follows: the sum of one times the number of 26 hour principals, 0 75 times the number of 19 hour principals, and 0 5 times the number of 13 3 -2 (corticosteroids), and 3-3 (prophylaxis of asthma) of the British National Formulary would have been preferable, but FHSA averages for these headings would have been necessary, and these are not available from the PACT information sent to practices. Data on prescribing costs for antibiotics might have been helpful as they might have shown considerable cost savings, but we did not seek this information. Conversion of FHSA averages from the figures given by the practices to cost per 1000 patients may contain potential errors. In the PACT reports FHSA averages are calculated on the basis of the number of "prescribing units" in the practice, not the number of patients. Each patient on the lists who is older than 65 years is regarded as three prescribing units, and differences in patients' age profiles among practices may have influenced our findings. The FHSA average figures should properly be regarded as costs per quarter per 1000 patients of similar age profile.
Despite these potential sources of error our results provide some useful data which suggest that high prescribing costs in asthma prophylaxis and respiratory drugs overall may be associated with savings in other areas of care. The practices surveyed had average total prescribing costs which were less than those of both their own FHSA and FHSAs combined. The reasons for this are open to speculation, but one possible factor must be that practice teams including a member with an interest in asthma are more likely to be among those trying to deliver better care in general and rational prescribing in particular. It is also clear, however, that the prescribing costs for respiratory drugs for this sample were significantly higher than those for their FHSA and FHSAs combined.
Individual members of the group on average had higher prescribing costs for respiratory drugs than their practices, probably reflecting the disproportionately higher number of asthmatic patients they see and prescribe for. However, the data on individuals' prescribing costs must be interpreted with caution. The concept of the notional share of the list described is an attempt to compare between individual practitioners, but it may well not reflect responsibility for patient care or prescribing. Moreover, PACT data do not identify repeat prescriptions nor clinical responsibility by individual doctors. The PACT data we analysed might have included large numbers of prescriptions written by the partners of the doctors surveyed, as we did not ask about the existence of personal lists or protocols for use of prescription pads. Nevertheless, the fact that the practices' overall prescribing costs for respiratory drugs were higher than the average for their FHSA suggests that index general practitioners were not simply "cornering the practice market."
The government's working paper on indicative prescribing budgets in 1989 made clear the wide variations in prescribing between FHSAs -from £26 000 to £40 000 per 1000 patients in 1986-7.'1 Our results reinforce this for total prescribing costs and prescribing costs for respiratory drugs for the practices and FHSAs in our sample. Total prescribing costs for FHSAs in our survey varied from £7302 to £13 441 per 1000 patients per quarter and prescribing costs for respiratory drugs from £184 to £1557. This wide variation cannot simply be attributed to variations in the population and must be influenced by doctors' behaviour in relation to prescribing, investigations, and referralwhich are known to vary widely. Investigating this variation is beset with difficulties.'8 For example, one study of general practitioners with high and low referral rates not only failed to elucidate appreciable differences in the doctors or their practices but also showed no consistent link with prescribing or use of investigations.*
The estimation of indicative budgets on the basis of FHSA averages may be rather misleading if prescribing is to be made more rational as well as cheaper, particularly in specific areas such as management of asthma. Indeed, applying national averages to prescribing for asthma may also be misleading as undertreatment is so widespread. FHSAs should examine high prescribing costs for respiratory drugs incurred by individual general practitioners and practices with great caution, taking into account if possible the asthma service they provide. If FHSAs were to target high costs in individual prescribing groups as potentially undesirable these practices might be subject to unnecessary and inappropriate investigation.
In conclusion, we showed that individual general practitioners with an interest in asthma have on average higher prescribing costs for respiratory and prophylactic drugs than those of their practice. Much more importantly, their practices have on average higher prescribing costs for respiratory drugs per 1000 patients than their FHSAs but lower total costs. High prescribing costs must not be examined for individual doctors, nor for one therapeutic category in isolation, but should be seen in the context of total practice prescribing costs, and FHSAs and their medical advisors need to be aware of this important concept. High prescribing costs for respiratory drugs may be an indicator of good prescribing for asthma and low costs an indicator of bad prescribing, but an essential next step is to relate differences in costs to differences in practices' prevalence of diagnosed asthma as a percentage of list size, hospital admission rates and outpatient referrals, need for rescue treatments such as oral steroids and acute nebulisations, and time missed from work or school.
